The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use. One of the most recent organizations to create utilization guidelines is the American Congress of Obstetricians and Gynecologists (ACOG), which released its guidelines in April 2015. Other guidelines are available from state medical boards, and the American Medical Association released a statement on the topic in 2010. The American Nurses Association (ANA) released a tool kit, which contain the ANA’s social networking principles, tips for nurses using social media, social media webinar, and a fact sheet.
ANA’s principles include not transmitting or posting identifiable patient information, observing patient-nurse boundaries, and being aware that colleagues and others have the ability to view what is posted. Nurses should utilize privacy settings and ideally, have separate personal and professional online accounts. Nurses also need to bring harmful content to the attention of appropriate individuals or authorities. The ANA notes that misuse of social media can not only damage the individual nurse’s reputation, but may damage the reputation of the nursing profession as well. The toolkit is available at http://www.nursingworld.org/socialnetworkingtoolkit.aspx.
Social Media: Risks and Benefits
The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use.
The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use. One of the most recent organizations to create utilization guidelines is the American Congress of Obstetricians and Gynecologists (ACOG), which released its guidelines in April 2015. Other guidelines are available from state medical boards, and the American Medical Association released a statement on the topic in 2010. The American Nurses Association (ANA) released a tool kit, which contain the ANA’s social networking principles, tips for nurses using social media, social media webinar, and a fact sheet.
ANA’s principles include not transmitting or posting identifiable patient information, observing patient-nurse boundaries, and being aware that colleagues and others have the ability to view what is posted. Nurses should utilize privacy settings and ideally, have separate personal and professional online accounts. Nurses also need to bring harmful content to the attention of appropriate individuals or authorities. The ANA notes that misuse of social media can not only damage the individual nurse’s reputation, but may damage the reputation of the nursing profession as well. The toolkit is available at http://www.nursingworld.org/socialnetworkingtoolkit.aspx.
Newsletter
Stay up to date on recent advances in oncology nursing and patient care.
Selinexor Maintenance Offers Durable Benefit in Advanced Endometrial Cancer
In TP53 wild-type advanced or recurrent endometrial cancer, selinexor improved multiple time-to-event outcomes vs placebo.
What New Cancer Drugs Were Approved in 2023?
In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.
NCCN Adds Taletrectinib to ROS1+ NSCLC Recommendations
The NCCN has added taletrectinib to its recommendations for use in all lines of treatments for non–small cell lung cancer harboring ROS1 mutations.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases
Adjuvant aspirin did not reduce recurrence or improve survival in patients with CRC liver metastases, phase 3 data showed at the 2025 ASCO Meeting.
Q&A: Subcutaneous Daratumumab Eases Myeloma Time Burden
Subcutaneous daratumumab makes it easier for patients to find appointments that fit with their lifestyles and schedules, according to Gina Fries, PA-C.
Selinexor Maintenance Offers Durable Benefit in Advanced Endometrial Cancer
In TP53 wild-type advanced or recurrent endometrial cancer, selinexor improved multiple time-to-event outcomes vs placebo.
What New Cancer Drugs Were Approved in 2023?
In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.
NCCN Adds Taletrectinib to ROS1+ NSCLC Recommendations
The NCCN has added taletrectinib to its recommendations for use in all lines of treatments for non–small cell lung cancer harboring ROS1 mutations.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases
Adjuvant aspirin did not reduce recurrence or improve survival in patients with CRC liver metastases, phase 3 data showed at the 2025 ASCO Meeting.
Q&A: Subcutaneous Daratumumab Eases Myeloma Time Burden
Subcutaneous daratumumab makes it easier for patients to find appointments that fit with their lifestyles and schedules, according to Gina Fries, PA-C.
Latest Conference Coverage
No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases
Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break
Genomic Changes May Drive Sotorasib KRAS G12C+ Combo Resistance in CRC
Relacorilant/Nab-Paclitaxel Is Convenient, Safe in Ovarian Cancer